Liraglutide and Semaglutide, a weekly GLP- 1 receptor agonist, was finally approved for both indications
117 SejvarJJCurnsATWelburgLJonesJFLundgrenLMCapuronLet al
Signs you're ready to move to the next dose: GI symptoms (nausea, vomiting, diarrhea) have resolved or are minimal for at least 7 consecutive days Appetite suppression remains noticeable but you sense a plateau effect developing at the current dose You have completed at least 4 full weeks at the current dose level You have no significant intercurrent illness that might confuse attribution of new symptoms Signs to wait: Ongoing nausea or vomiting, even if mild, at the end of the current dose phase A recent GI illness (unrelated to the medication) that makes it hard to attribute current symptoms A major life stressor or schedule disruption that might amplify side effects Fewer than 4 weeks at the current dose, regardless of how you feel When in doubt, an additional week at the current dose costs very little
However, this significant weight reduction leads to fat loss, especially in the face
Excess weight is a risk factor for chronic kidney disease (CKD), as obesity is linked to conditions like Type 2 diabetes and high blood pressure, which can harm your kidneys
In agreement with our data, two recent transcriptomics studies failed to detect vesicular glutamate transporters in any enteroendocrine cell types 4,89